Governments and healthcare systems worldwide are implementing mass screening programs for Type 2 diabetes and pre-diabetes, utilizing HbA1c testing, glucose tolerance screening, and risk stratification algorithms in primary care settings
The FDA prescribing information for semaglutide and tirzepatide lists fatigue as an adverse reaction occurring in clinical studies, with incidence rates typically ranging from 5-11% depending on the specific product and dosage
Our physicians work with each patient individually to identify the right treatment approach based on their health history, goals, and preferences
Until now, no pharmacologic treatment had received FDA approval specifically for MASH, leaving a significant unmet clinical need
See our GLP-1 cost guide
Patients understand they are receiving a solution built on science rather than marketing claims